Clinical Trial Update: Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluates a combination of surufatinib with gemcitabine, cisplatin, and durvalumab or pembrolizumab for advanced biliary tract cancer and is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)
• Pembrolizumab (pembrolizumab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Dai, Guanghai | Conditions: Advanced Biliary Tract Cancer | Phase 2 | Status: RECRUITING